Research progress on whole-course management of non-small cell lung cancer patients with BRAF V600E mutation
10.3969/j.issn.1671-8348.2024.05.026
- VernacularTitle:BRAF V600E突变非小细胞肺癌患者全程管理的研究进展
- Author:
Lin YANG
1
;
Yubo WANG
Author Information
1. 重庆大学附属江津医院呼吸与危重症医学科,重庆 402260
- Keywords:
non-small cell lung cancer;
BRAF V600E;
treatment;
whole-course management;
review
- From:
Chongqing Medicine
2024;53(5):782-786
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the malignant tumor with the highest incidence and death in the world,among which non-small cell lung cancer(NSCLC)accounts for the largest proportion.The BRAF gene is a proto-on-cogene associated with poor prognosis in NSCLC,represented by BRAF V600E mutations.In recent years,the diagnosis and treatment of NSCLC patients with BRAF V600E mutation has become the focus of accurate di-agnosis and treatment of lung cancer,especially its whole-course management.There are many related studies on targeting,immunotherapy and chemotherapy for patients with BRAF V600E mutation.This paper reviewed the relevant research progress at home and abroad.
